Subscribe
ftc-istock-530746621-rivernorthphotography
RiverNorthPhotography / iStockphoto.com
29 March 2017Americas

FTC hails M&A activity in ‘historic’ 2016

Last year was a historic one for the US Federal Trade Commission, according to its “ Annual Highlights” report, issued yesterday.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

More on this story

Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.

More on this story

Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?